Anemia of cancer improving/prophylactic agent

• US 9,539,225 B2
• Filed: 10/05/2012
• Issued: 01/10/2017
• Est. Priority Date: 10/12/2011
• Status: Active Grant

• Current Assignee: SBI Pharmaceuticals Co., Ltd. (Ajinomoto Co., Inc.)
• Original Assignee: SBI Pharmaceuticals Co., Ltd. (Ajinomoto Co., Inc.)
• Inventors: Tanaka, Tohru, Nakajima, Motowo, Abe, Fuminori, Kawata, Satofumi, Takahashi, Kiwamu
• Primary Examiner(s): TRAN, MY CHAU T
• Application Number:
  US14/350,675
• Publication Number:
  US 20140288173A1
• Time in Patent Office: 1,558 Days
• Field of Search: 514/502, 514/561, 562/567
• US Class Current: 1/1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/197 the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid carnitine A61K31/205
• CPC Class Codes: A61K 31/216 of acids having aromatic rings, e.g. benactizyne, clofibrate
• CPC Class Codes: A61K 31/22 of acyclic acids, e.g. pravastatin
• CPC Class Codes: A61K 31/222 with compounds having aromatic groups, e.g. dipivefrine, ibopamine
• CPC Class Codes: A61K 31/295 Iron group metal compounds
• CPC Class Codes: A61K 33/06 Aluminium, calcium or magnesium; Compounds thereof , e.g. clay
• CPC Class Codes: A61K 33/26 Iron; Compounds thereof
• CPC Class Codes: A61K 33/30 Zinc; Compounds thereof
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/06 Antianaemics

Abstract

A method for ameliorating and/or preventing cancerous anemia includes administering to a subject in need thereof an agent containing 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt thereof. Preferably, these ALAs contain a metal-containing compound, such as sodium ferrous citrate. The above-mentioned ALAs, ALA; various esters such as ALA methylester, ALA ethylester, ALA propylester, ALA butylester, and ALA pentylester; and hydrochlorides, phosphates, and sulfates, and the like of these ALA esters are preferred examples.

Claims

1. A method for ameliorating and/or preventing cancerous anemia, the method comprising administering to a subject having cancerous anemia an agent comprising a compound represented by the following formula (I) or a salt thereof:

2. The method according to claim 1, wherein the agent further comprises one or more metal-containing compounds.

3. The method according to claim 2, wherein the metal-containing compound is a compound containing iron, magnesium, zinc, nickel, vanadium, copper, chrome, molybdenum, or cobalt.

4. The method according to claim 2, wherein the metal-containing compound is a compound containing iron, magnesium, or zinc.

5. The method according to claim 2, wherein the metal-containing compound is a compound containing iron.

6. The method according to claim 1, wherein the agent further comprises one or more metal-containing compounds.

7. The method according to claim 6, wherein the one or more metal-containing compound is a compound containing iron, magnesium, zinc, nickel, vanadium, copper, chrome, molybdenum, or cobalt.

8. The method according to claim 6, wherein the one or more metal-containing compound is a compound containing iron, magnesium, or zinc.

9. The method according to claim 6, wherein the one or more metal-containing compound is a compound containing iron.

10. The method according to claim 1, wherein the cancer is leukemia.